HBV-IN-30
HBV-IN-30 (ex44), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-30 has the potential for the research of HBV infection.
For research use only. We do not sell to patients.
- CAS No.: 2413192-92-2
- Formula: C22H18BrClO6
- Molecular Weight:493.73
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
HBV-IN-30 (ex44; 24 h) inhibits HBeAg levels and cell viability with an IC50 value of 0.57 μM in HepDES19 cells. HepDES19 is the cell line that produces cccDNA[1].
HBV-IN-30 (5 days) decreases cccDNA levels in HepDES19 cells in a dose-dependent manner[1].
HBV-IN-30 (9 days; primary human hepatocyte (PHH)) has anti-HBV effect and inhibits HBeAg with an IC50 value of 0.04 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2413192-92-2
-
Molecular Weight 493.73
-
Formula C22H18BrClO6
-
SMILES
ClC1=C2C(C(C=C(C3=CC(Br)=C(C=C3)OCCO[C@@H]4C[C@@H](C4)C(O)=O)O2)=O)=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
HBV-IN-30 Related Classifications
HY-148781 Related Classifications
Powered by Bioz